AC2993 12-Week Profile in Type 2 Diabetes Open-label Data Show Progressive Reductions in HbA1c
- Mean reductions in HbA1c of 1.5% at 12 weeks
- No increase in mean body weight
- Adverse event profile similar to Phase 2 trials
- Most common adverse event: mild to moderate, transient nausea